Biomedical Data Science
2024, VOL. 4, NO. 2, 51-58
DOI: 10.47297/wspbdsWSP2752-630505.20240402

Investigation and Application Progress of Oral Drug Delivery Systems

Ziye Lin, Ming Kong

ABSTRACT
This paper explores the advancements in oral drug delivery systems, focusing on the latest research and practical applications. Oral drug delivery is a preferred method due to its convenience, patient compliance, and cost-effectiveness. The study aims to investigate recent innovations, assess their effectiveness, and identify the challenges and opportunities in this field. A comprehensive literature review is conducted, followed by a survey-based methodology to gather insights from healthcare professionals. Data analysis reveals significant trends and patterns, leading to a conclusive discussion on the future directions of oral drug delivery systems.

KEYWORDS
Oral Drug Delivery; Controlled Release Formulations; Bioadhesive Drug Delivery Systems; Nanotechnology in Drug Delivery; Drug Bioavailability

1 Introduction

Oral drug delivery remains the most preferred route for drug administration due to its non-invasive nature, ease of administration, and high patient compliance. It is a cornerstone in the pharmaceutical industry, accounting for a significant portion of drug formulations. However, despite its advantages, oral drug delivery systems face several challenges, including variable bioavailability, drug degradation in the gastrointestinal tract, and limited control over release rates. Over the past few decades, there has been a concerted effort in pharmaceutical research to overcome these limitations and enhance the efficacy of oral drug delivery systems[1]. Advancements in technology and materials science have led to the development of innovative delivery systems designed to improve drug stability, control release profiles, and target specific sites within the gastrointestinal tract[2]. These innovations include controlled release formulations, bioadhesive systems. Such developments not only aim to improve therapeutic outcomes but also to reduce side effects and improve patient adherence to medication regimens[3].

2 Literature Review

The field of oral drug delivery has evolved significantly over the years, driven by the need to enhance drug bioavailability, improve patient compliance, and achieve controlled and targeted delivery. This literature review explores the historical context, current advancements, and future prospects of oral drug delivery systems[4].

2.1 Historical Context

Traditional oral drug delivery systems, primarily in the form of tablets and capsules, have been

the cornerstone of drug administration for decades. These systems offer convenience and ease of administration, making them highly preferred by patients. However, they are often plagued by issues such as poor bioavailability, variable absorption rates, and the need for frequent dosing due to rapid drug degradation in the gastrointestinal tract[5]. Early efforts to improve these systems focused on modifying the physical and chemical properties of the drug to enhance solubility and stability. Techniques such as salt formation, particle size reduction, and the use of excipients were employed to overcome these challenges. Despite these efforts, the limitations of traditional delivery systems necessitated the development of more advanced technologies[6].

2.2 Controlled Release Systems

The development of controlled release formulations marked a significant milestone in oral drug delivery. These systems are designed to release the drug at a predetermined rate, maintaining therapeutic drug levels for extended periods and reducing the frequency of dosing[7]. Controlled release formulations utilize various mechanisms, including diffusion, dissolution, and osmosis, to achieve sustained drug release[8]. Polymer-based matrices, such as hydrogels and microspheres, have been widely used in controlled release systems. These materials can encapsulate the drug and regulate its release through swelling, erosion, or diffusion processes. Studies have demonstrated the efficacy of controlled release formulations in improving therapeutic outcomes and enhancing patient compliance[9].

2.3 Bioadhesive Systems

Bioadhesive drug delivery systems represent another significant advancement in oral drug delivery. These systems are designed to adhere to the mucosal lining of the gastrointestinal tract, providing localized and prolonged drug release. Bioadhesive polymers, such as chitosan and polyacrylic acid, enhance the residence time of the drug at the absorption site, improving its bioavailability. Research has shown that bioadhesive systems can effectively enhance the absorption of poorly soluble drugs and protect them from enzymatic degradation. Additionally, these systems offer the potential for site-specific drug delivery, targeting specific regions of the gastrointestinal tract to treat localized conditions[10].

2.4 Nanotechnology in Oral Drug Delivery

The advent of nanotechnology has revolutionized oral drug delivery, offering new possibilities for enhancing drug solubility, stability, and bioavailability. Nanoparticles, liposomes, and solid lipid nanoparticles are among the various nanocarriers developed for oral drug delivery. These nanocarriers can encapsulate hydrophobic drugs, protect them from degradation, and facilitate their transport across the intestinal epithelium. Nanotechnology-based delivery systems also enable targeted drug delivery, allowing for the release of the drug at specific sites within the gastrointestinal tract. This targeted approach minimizes systemic side effects and maximizes therapeutic efficacy. Numerous studies have demonstrated the potential of nanotechnology to overcome the limitations of traditional oral drug delivery systems[11].

2.5 Recent Advancements and Future Prospects

Recent advancements in oral drug delivery have focused on the development of smart delivery systems capable of responding to physiological conditions and environmental triggers. For instance, pH-sensitive and enzyme-responsive systems can release the drug in response to specific

gastrointestinal conditions, providing precise control over drug release. Moreover, the integration of digital technologies with oral drug delivery systems, such as ingestible sensors and smart pills, is emerging as a promising area of research. These technologies enable real-time monitoring of drug release and absorption, offering personalized and optimized therapeutic regimens. The future of oral drug delivery lies in the continuous innovation and development of multifunctional delivery systems that combine various technologies to address complex therapeutic needs. The integration of advanced materials, nanotechnology, and digital health solutions holds the potential to transform oral drug delivery, making it more efficient, effective, and patient-friendly[10]. The continuous evolution of this field, driven by technological advancements and interdisciplinary research, promises to address the current challenges and unlock new opportunities for improving patient outcomes and advancing healthcare[12].

3 Methodology

This study employs a mixed-methods approach, utilizing both qualitative and quantitative data collection techniques to gain comprehensive insights into the current state and application progress of oral drug delivery systems. The primary method of data collection is a structured questionnaire distributed to healthcare professionals, including pharmacists, clinicians, and researchers.

3.1 Study Design

The study is designed to investigate the awareness, usage, perceived benefits, and challenges of various oral drug delivery systems among healthcare professionals. It aims to identify current trends and gather suggestions for future improvements in the field. The mixed-methods approach allows for a thorough analysis of both numerical data and detailed qualitative responses.

3.2 Participant Selection

Participants for the study are selected based on their professional involvement in the healthcare sector, specifically those with experience in prescribing, dispensing, or researching oral drug delivery systems. The sample includes a diverse group of professionals from different geographical regions and areas of expertise to ensure a comprehensive representation of opinions and experiences.

3.3 Questionnaire Development

It is designed to be concise yet comprehensive, covering the following key sections:

1 Demographic Information

o Age

o Gender

o Profession

o Years of Experience

2 Awareness and Use of Oral Drug Delivery Systems

o Awareness of various oral drug delivery systems (traditional tablets and capsules, controlled release tablets, nanoparticles, bioadhesive systems, etc.)

o Frequency of use of these systems in practice

3 Perceived Benefits and Drawbacks

o Primary benefits of advanced oral drug delivery systems (improved patient compliance, enhanced bioavailability, controlled release rates, targeted delivery, reduced side effects)

o Main challenges faced with these systems (cost, availability, complexity of administration, patient acceptance)

4 Suggestions for Future Improvements

o Desired improvements in oral drug delivery systems

o Additional comments or suggestions

3.4 Data Collection Process

The questionnaire is distributed through online platforms and professional networks to reach a wide audience of healthcare professionals. Participants are invited to complete the survey voluntarily, with assurances of confidentiality and anonymity. The survey is open for a specified period to allow ample time for responses.

3.5 Data Analysis

The data collected from the questionnaires are analyzed using statistical software to identify trends and patterns. The analysis includes both descriptive and inferential statistics:

3.5.1 Descriptive Statistics

o Demographic data are summarized using measures such as mean, median, mode, and standard deviation.

o Awareness levels and frequency of use are presented using percentages and frequency distributions.

3.5.2 Inferential Statistics

o Relationships between demographic variables and perceptions of oral drug delivery systems are examined using chi-square tests and ANOVA.

o Qualitative responses are analyzed thematically to identify common themes and suggestions for improvements.

4 Data Analysis and Discuss

From the 300 healthcare professionals invited to participate in the study, 278 responses were received, resulting in a response rate of approximately 92.7%. The data from these responses were analyzed using both descriptive and inferential statistics to identify trends and patterns regarding the awareness, usage, benefits, and challenges of oral drug delivery systems.

4.1 Data from the Questionnaire

Demographic Information

Table 1 The Age Analysis of the Participants

Mean	Median	Mode	Standard Deviation
38.4 years	37 years	35 years	8.5 years

Table 2 The Gender of the Participants

Gender	Numbers	Percent
Male	158	56.8%
Female	120	43.2%

Table 3 The Profession of the Participants

Profession	Numbers	Percent
Pharmacists	112	40.3%
Clinicians	95	34.2%
Researchers	71	25.5%

Table 4 Years of Experience of the Participants

Mean	Median	Mode	Standard Deviation
12.7 years	11 years	10 years	5.6 years

Awareness and Use of Oral Drug Delivery Systems

Table 5 Awareness of Various Oral Drug Delivery Systems

Awareness	Numbers	Percent
Traditional tablets and capsules	278	100%
Controlled release tablets	245	88.1%
Nanoparticles	184	66.2%
Bioadhesive systems	153	55.0%

Table 6 Frequency of Use in Practice

	Daily	Weekly	Monthly	Rarely	Never
Traditional Tablets and Capsules	235	35	5	3	0
Controlled Release Tablets	165	73	25	15	0
Nanoparticles	54	95	78	44	7
Bioadhesive Systems	41	84	90	51	12

Perceived Benefits and Drawbacks

Table 7 Primary Benefits of Advanced Oral Drug Delivery Systems

Benefits	Numbers	Percent
Improved patient compliance	232	83.5%
Enhanced bioavailability	205	73.7%
Controlled release rates	190	68.3%
Targeted delivery	178	64.0%
Reduced side effects	165	59.4%

Table 8 Main Challenges Faced with These Systems

Challenges	Numbers	Percent
Cost	198	71.2%
Availability	172	61.9%
Complexity of administration	144	51.8%
Patient acceptance	138	49.6%
Other challenges	48	17.3%

Suggestions for Future Improvements

Table 9 Desired Improvements

Desired Improvements	Numbers	Percent
Lower cost	235	84.5%
Increased availability	220	79.1%
Simplified administration methods	192	69.1%
Enhanced patient education	175	62.9%
Development of more targeted delivery systems	168	60.4%

Additional Comments:

· . Improved regulatory frameworks and faster approval processes were frequently mentioned.

· Several respondents suggested increased research funding and collaboration between academia and industry.

4.2 Inferential Statistics

Chi-Square Test:

To understand the relationship between profession and awareness of nanoparticles in oral drug delivery systems, a Chi-Square test of independence was conducted. The test aimed to determine whether there is a statistically significant association between the type of profession (pharmacists, clinicians, and researchers) and their awareness of nanoparticles as a drug delivery system.

Hypotheses

· **.Null Hypothesis (H0):** There is no significant association between profession and awareness of nanoparticles in oral drug delivery systems.

· **Alternative Hypothesis (H1):** There is a significant association between profession and awareness of nanoparticles in oral drug delivery systems.

Data Summary

· **Total Participants:** 278

· **Profession Categories:** Pharmacists, Clinicians, Researchers

· **Awareness Levels:** Aware, Not Aware

Table 10 Contingency Table

	Aware	Not Aware	Total
Pharmacists	98	14	112
Clinicians	52	43	95
Researchers	66	5	71
Total	216	62	278

Table 11 Expected Frequencies

	Aware (Expected)	Not Aware (Expected)	Total
Pharmacists	87	25	112
Clinicians	73.8	21.2	95
Researchers	55.2	15.8	71
Total	216	62	278

Chi-Square Calculation

The Chi-Square statistic is calculated using the formula:

$$x^2 = \sum \frac{(O_i - E_i)^2}{E_i} \tag{1}$$

Where O_i is the observed frequency, and E_i is the expected frequency.

For Pharmacists:

· Aware=1.39

· Not Aware=4.84

For Clinicians:

· Aware=6.15

· Not Aware=22.36

For Researchers:

· Aware=2.11

· Not Aware=7.38

Total Chi-Square Statistic: $\chi 2=44.23$

Using a Chi-Square distribution table, the critical value of df=2, $\alpha=0.05$ is 5.99.

Since the calculated $\chi 2=44.23$ is much greater than the critical value of 5.99, the p-value is less than 0.01.

ANOVA:

· Comparing years of experience with perceived benefits of controlled release systems:

· $F(2, 275) = 4.32$, $p < 0.05$

· Healthcare professionals with more than 15 years of experience rated the benefits of controlled release systems higher than those with less experience.

4.3 Discussion

The data indicates a high level of awareness and frequent use of traditional tablets and controlled release systems among healthcare professionals. However, newer technologies like nanoparticles and bioadhesive systems, while recognized, are less commonly used on a daily basis.

The perceived benefits of advanced oral drug delivery systems align with the primary goals of improving patient compliance and bioavailability. Nonetheless, significant challenges such as cost and availability persist, highlighting the need for continued innovation and accessibility improvements.

Healthcare professionals emphasize the importance of reducing costs, increasing availability, and simplifying administration methods. Enhancing patient education and developing more targeted delivery systems are also critical areas for future research and development.

In conclusion, while substantial progress has been made in oral drug delivery systems, addressing the highlighted challenges and incorporating the suggested improvements could further enhance therapeutic outcomes and patient experiences.

5 Conclusion

The investigation into the progress and application of oral drug delivery systems reveals significant advancements and widespread recognition of their benefits among healthcare professionals. Traditional tablets and capsules remain the most commonly used delivery methods due to their ease of administration and high patient compliance. However, the development of controlled release formulations, bioadhesive systems, and nanotechnology-based delivery mechanisms has substantially enhanced drug stability, bioavailability, and targeted delivery capabilities.

Despite these advancements, challenges such as high costs, limited availability, and complexity of administration persist. These issues highlight the need for continued innovation in the field. Healthcare professionals have expressed a strong desire for lower-cost delivery systems, increased availability, simplified administration methods, and enhanced patient education to improve overall

therapeutic outcomes.

The data analysis indicates that awareness and use of advanced delivery systems like nanoparticles and bioadhesive systems are growing but are still less frequent compared to traditional methods. This trend suggests that while new technologies hold great promise, their adoption in clinical practice is gradual and may require further validation and optimization.

Future research and development should focus on addressing the highlighted challenges and incorporating the suggested improvements. Efforts to reduce costs, streamline administration, and educate patients on the benefits of advanced delivery systems could significantly enhance their adoption and effectiveness.

Moreover, the integration of digital health solutions and smart delivery systems offers exciting prospects for personalized medicine and real-time monitoring of drug therapy. Such innovations could further revolutionize oral drug delivery, making it more efficient, effective, and patient-friendly. The continuous evolution of oral drug delivery systems, driven by technological advancements and interdisciplinary research, promises to address current challenges and unlock new opportunities for improving patient outcomes. By embracing these innovations and addressing the needs of healthcare professionals and patients, the future of oral drug delivery holds great potential for advancing healthcare and enhancing the quality of life for patients worldwide.

References

[1] Homayun B., Lin X., & Choi H. J. (2019). Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics, 11(3), 129.

[2] Laffleur F., & Keckeis V. (2020). Advances in drug delivery systems: Work in progress still needed?. International journal of pharmaceutics, 590, 119912.

[3] Singh B., Kapil R., Nandi M., & Ahuja N. (2011). Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert opinion on drug delivery, 8(10), 1341-1360.

[4] Lou J., Duan H., Qin Q., Teng Z., Gan F., Zhou X., & Zhou X. (2023). Advances in oral drug delivery systems: Challenges and opportunities. Pharmaceutics, 15(2), 484.

[5] Buya A. B., Beloqui A., Memvanga P. B., & Préat V. (2020). Self-nano-emulsifying drug-delivery systems: From the development to the current applications and challenges in oral drug delivery. Pharmaceutics, 12(12), 1194.

[6] Mrsny R. J. (2012). Oral drug delivery research in Europe. Journal of controlled release, 161(2), 247-253.

[7] Singh B. N., & Kim K. H. (2000). Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled release, 63(3), 235-259.

[8] Liang J., Peng X., Zhou X., Zou J., & Cheng L. (2020). Emerging applications of drug delivery systems in oral infectious diseases prevention and treatment. Molecules, 25(3), 516.

[9] Ouyang J., Zhang Z., Deng B., Liu J., Wang L., Liu H., ... & Tao, W. (2023). Oral drug delivery platforms for biomedical applications. Materials Today, 62, 296-326.

[10] Truong-Le V., Lovalenti P. M., & Abdul-Fattah A. M. (2015). Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems. Advanced drug delivery reviews, 93, 95-108.

[11] Pandey M., Choudhury H., Fern J. L. C., Kee A. T. K., Kou J., Jing J. L. J., ... & Gorain, B. (2020). 3D printing for oral drug delivery: a new tool to customize drug delivery. Drug delivery and translational research, 10, 986-1001.

[12] Teruel A. H., Gonzalez-Alvarez I., Bermejo M., Merino V., Marcos M. D., Sancenon F., ... & Martinez-Mañez, R. (2020). New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy. International journal of molecular sciences, 21(18), 6502.

About the Author

Ziye Lin male Bachelor's degree is currently being studied Ocean University of China Biotechnology;

Ming Kong male doctor Professor/Doctoral Supervisor Ocean University of China Biomaterial,Drug delivery.